Bristol-Myers Squibb Company (NYSE:BMY) is one of the best medical research stocks to buy according to hedge funds. Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted the price target on the stock to $40 from $37 while keeping an Underweight rating on the shares. The firm told investors in a research note that whi ...

Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 10 Most Profitable Undervalued Stocks to Buy, with multiple firms raising their price targets following positive earnings reports and promising pipeline developments [1][3][5]. Price Target Updates - Guggenheim raised its price target on BMY to $72 from $62, citing a significant increase in the estimated probability of success for key drugs [1]. - Bank of America increased its price target to $68 from $64, highlighting strong fourth-quarter results and positive fiscal 2026 guidance [3]. - Wells Fargo raised its price target to $60 from $55, indicating potential upside if the growth portfolio exceeds current expectations [4]. - Citi lifted its price target to $64 from $60, maintaining a Neutral rating while emphasizing the importance of pipeline execution for future share upside [5]. Financial Performance - Bristol-Myers reported fourth-quarter revenue of $12.5 billion, surpassing the consensus estimate of $12.28 billion, indicating strong performance and momentum in its growth portfolio [6]. Pipeline and Future Outlook - The company is expected to have a data-rich 2026, with multiple pivotal pipeline readouts anticipated in the latter half of the year, which could significantly impact its growth trajectory [6]. - Analysts noted that the positive Phase 3 read-across from Bayer's SSP data helps to mitigate risks associated with the milvexian opportunity [3].